News for AB Science S.A. (0Q77.L)

Blueprint Medicines generates strong revenue growth from its FDA-approved product AYVAKIT, reporting $92.5 million in Q1'24 net product revenues. Read more here.

PRESS RELEASE SUCCESS OF THE CAPITAL INCREASE BY PRIVATE PLACEMENT FOR AN AMOUNT OF 15 MILLION EUROS Paris, April 24, 2023, 8am CET AB Science S.A. , announces today the success of its capital... | April 24, 2023

PRESS RELEASE FOCUS OF THE DEVELOPMENT STRATEGY ON AMYOTROPHIC LATERAL SCLEROSIS WITH THE MASITINIB PLATFORM AND ON THE SECOND MICROTUBULE PLATFORM AND SEARCH FOR PARTNERSHIPS FOR NON-RARE DISEASE... | April 21, 2023

PRESS RELEASE AB SCIENCE ANNOUNCES THAT IT HAS SUBMITTED ITS RESPONSE TO THE DAY 120 QUESTIONS IN THE EMA REGULATORY REVIEW OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AND CLARIFIES THE NEW... | April 4, 2023

/PRNewswire/ -- The "Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy (Surgery,...

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Global Neuroimmunology Drugs Market By Indication...

Read AB Science S.A. (OTCMKTS:ABSCF) Short Interest Down 97.1% in June at ETF Daily News

Read AB Science S.A. (OTCMKTS:ABSCF) Sees Significant Increase in Short Interest at ETF Daily News

Read AB Science (OTCMKTS:ABSCF) Stock Price Down 1.7% at ETF Daily News